South Korea-based SK Biopharmaceuticals has announced the establishment of Mentis Care, Inc., a joint venture (JV) with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialise an artificial intelligence (AI)-based epilepsy management platform.
Since 2018, SK Biopharmaceuticals has built its proprietary expertise in AI-driven electroencephalography (EEG) and wearable device technologies with seizure detection and real-time monitoring. Mentis Care will leverage these technologies to develop a comprehensive digital platform that combines real-time seizure detection and prediction algorithms with clinical decision support tools, creating an integrated system for personalized patient care.
Mentis Care is located in the MaRS Discovery District in Toronto, Canada — one of North America's largest innovation hubs bringing research institutions, startups, and investors in life sciences and healthcare together. The company plans to expand its local team, strengthen academic and industry collaborations, and pursue clinical validation of its AI algorithms.
As a pharmaceutical company representing Latin America, Eurofarma leads business strategy planning and AI data learning of the venture. SK Biopharmaceuticals has collaborated with Eurofarma since 2022 to develop and commercialise its anti-seizure medication, cenobamate (US brand name: XCOPRI®) in Latin America. The partnership extends into digital healthcare through the joint venture establishment.
